Fentanyl for Breakthrough Pain in the Emergency Department

PHASE4TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

January 10, 2014

Primary Completion Date

October 22, 2014

Study Completion Date

October 22, 2014

Conditions
Pain
Interventions
DRUG

Fentanyl Nasal Spray

100 mcg nasal spray administered in each nostril.

DRUG

Hydromorphone PCA

Initial loading dose 0.2 mg with demand doses of 0.2 mg and lockout interval of 15 minutes. There will be no basal dose and the 8-hour dose limit will be 6.4 mg.

OTHER

Placebo Nasal Spray

1 placebo nasal spray administered in each nostril.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Archimedes Pharma US, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT01812759 - Fentanyl for Breakthrough Pain in the Emergency Department | Biotech Hunter | Biotech Hunter